Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double‐blind, placebo‐controlled trial

Seddighnia, Azadeh; Najafabadi, Borna Tadayon; Ghamari, Kiandokht; Noorbala, Ahmad Ali; Daryani, Naser Ebrahimi; Kashani, Ladan; Akhondzadeh, Shahin

doi:10.1111/jcpt.13032

Cited by 8 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

“…For their more recent 6-week-long RCT of vortioxetine (SSRI), Seddighnia et al (2020) recruited 72 patients and randomly assigned them to the vortioxetine ( n = 36) and placebo ( n = 36) groups [ 100 ]. The vortioxetine group demonstrated a greater increase in quality of life as compared to placebo ( p < 0.01), irrespective of depression or anxiety score changes [ 100 ]. Vortioxetine is a potent 5-HT3 receptor antagonist, and suppression of the 5-HT3 receptor improves IBS symptoms such as abdominal pain, stool consistency, and gastrointestinal motility, as shown by studies involving 5-HT3 blockers (alosetron and ramosetron) [ 101 , 102 ].…”

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

“…However, none of these adverse events was serious. Due to TCAs’ effect on muscarinic, alpha1 adrenergic, and histaminic receptors, side effects (such as drowsiness and dry mouth) are more common in patients taking TCAs as compared to SSRIs [ 97 , 100 ]. Given the shortcomings of extant studies, such as inadequate sample size, and inclusion of IBS patients with concomitant psychological disorders, as well as different subtypes of IBS [ 100 ], further investigations into the use of antidepressants in the management of IBS are warranted.…”

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

See 2 more Smart Citations

Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain

et al. 2021

View full text Add to dashboard Cite

Patients with irritable bowel syndrome (IBS) are increasingly presenting with a wide range of neuropsychiatric symptoms, such as deterioration in gastroenteric physiology, including visceral hypersensitivity, altered intestinal membrane permeability, and gastrointestinal motor dysfunction. Functional imaging of IBS patients has revealed several abnormalities in various brain regions, such as significant activation of amygdala, thinning of insular and anterior cingulate cortex, and increase in hypothalamic gray matter, which results in poor psychiatric and cognitive outcomes. Interrelations between the enteric and central events in IBS-related gastrointestinal, neurological, and psychiatric pathologies have compelled researchers to study the gut−brain axis—a bidirectional communication that maintains the homeostasis of the gastrointestinal and central nervous system with gut microbiota as the protagonist. Thus, it can be disrupted by any alteration owing to the gut dysbiosis or loss of diversity in microbial composition. Available evidence indicates that the use of probiotics as a part of a balanced diet is effective in the management of IBS and IBS-associated neurodegenerative and psychiatric comorbidities. In this review, we delineate the pathogenesis and complications of IBS from gastrointestinal and neuropsychiatric standpoints while also discussing the neurodegenerative events in enteric and central nervous systems of IBS patients and the therapeutic potential of gut microbiota-based therapy established on clinical and preclinical data.

show abstract

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

Section: Therapeutic Interventions In Ibs: the Role Of Antidepressantsmentioning

confidence: 99%

See 1 more Smart Citation

Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Multiple animal studies have shown that the SSRI fluvoxamine protects against the development of peptic ulcers through antioxidant and anti-inflammatory mechanisms [59,60]. Certain SSRIs may improve symptoms of irritable bowel syndrome (IBS); however, their efficacy is controversial, so they should only be prescribed in IBS patients with comorbid depression or anxiety [61,62].…”

Section: Gastrointestinal Disordersmentioning

confidence: 99%

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review

Edinoff

Akuly

Hanna

et al. 2021

Neurology International

158

View full text Add to dashboard Cite

Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, selective serotonin reuptake inhibitors (SSRIs) quickly became a mainstay of treatment for a variety of psychiatric disorders. The primary mechanism of action of SSRIs is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, subsequently increasing serotonin at the postsynaptic membrane in the serotonergic synapse. The six major SSRIs that are marketed in the USA today, fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine, are a group of structurally unrelated molecules that share a similar mechanism of action. While their primary mechanism of action is similar, each SSRI has unique pharmacokinetics, pharmacodynamics, and side effect profile. One of the more controversial adverse effects of SSRIs is the black box warning for increased risk of suicidality in children and young adults aged 18–24. There is a lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression. Adults, who do not have certain risk factors, which could be confounding factors, do not seem to carry this increased risk of suicidality. Ultimately, when prescribing SSRIs to any patient, a risk–benefit analysis must factor in the potential treatment effects, adverse effects, and dangers of the illness to be treated. The aim of this review is to educate clinicians on potential adverse effects of SSRIs.

show abstract

“…A subsequent (2019) RCT with 72 patients compared the effect of vortioxetine and placebo on quality of life of IBS patients. 2 Patients were 18 to 65 years old with a mean age of 31 years old and 43% male from a single center in Iran. Patients were included if they had moderate-to-severe IBS diagnosed using Rome IV criteria.…”

mentioning

confidence: 99%